Clinical Trials Browser

Phase 2 × Carcinoma, Non-Small-Cell Lung × Docetaxel × Clear all

NCT07528274 2026-04-14

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03158129 2026-04-06

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Phase 2 Completed

101 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT07001618 2026-04-03

IMMUNOLIFE2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05633667 2026-03-17

VELOCITY-Lung

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06841055 2026-03-13

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT02642042 2026-03-04

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Phase 2 Active not recruiting

60 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT04884282 2026-02-06

COMBI-TED

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07306624 2026-01-15

Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT07330050 2026-01-09

WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06029127 2026-01-05

A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Phase 2 Completed

35 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT03137771 2025-11-25

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 2 Active not recruiting

218 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05020457 2025-09-26

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT04725188 2025-08-15

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

Phase 2 Completed

255 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03739710 2025-06-15

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

175 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06929936 2025-06-08

PROTECT-1

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01652820 2025-05-23

GECP0008

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT04364620 2025-04-06

AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

Phase 2 Completed

35 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05800587 2025-04-04

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04880863 2025-03-03

NT-NAP-102-1

Phase 2 Completed

38 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05599789 2025-02-18

KeyPemls-004

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03971474 2024-09-03

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Phase 2 Completed

166 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05878028 2024-05-23

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03833440 2024-05-03

PIONeeR

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06182800 2023-12-27

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03845270 2023-12-19

R2D2

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT05863325 2023-11-07

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01750281 2023-10-24

SELECT-2

Phase 2 Completed

212 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03228186 2023-10-23

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Phase 2 Terminated

40 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT00118131 2023-08-15

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2 Terminated

49 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01708993 2023-08-04

Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02607423 2023-05-25

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00301808 2023-05-06

Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 2 Completed

29 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04863248 2023-04-14

PRESERVE 4

Phase 2 Terminated

10 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT00970684 2022-08-16

Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2 Completed

13 enrolled 9 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00097851 2022-06-27

Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00103389 2022-06-27

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04878107 2022-05-02

SABRE

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03770299 2022-03-24

CheckMate 9TN

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT01059188 2022-03-11

Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03798743 2022-03-02

SUCCESS

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03647488 2022-01-24

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Phase 2 Completed

18 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT01741155 2021-10-13

Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02387216 2021-10-12

SHERLOC

Phase 2 Terminated

153 enrolled 19 charts

Fibromatosis, Gingival, 2, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT02450539 2021-08-13

A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer

Phase 2 Completed

159 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung